2026 Q2 - tulosraportti
59 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 312 | ||
| 153 | ||
| 783 | ||
| 167 | ||
| 2 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sitten · MuokattuTraders week. A lot is happening now in Circio. Many collaborations, many results and strategies to be evaluated. Remember that there have been a flurry of failed studies in gene and cell therapy studies. Initiated too early a couple three years ago. Novartis, Lilly etc are cutting studies in phase 2, Lilly most recently yesterday in Alzheimer's. The arguably worst is last year's Astra Zeneca acquisition of EsoBiotec for 1 billion USD which failed with fatalities less than 6 months after payment in phase 1 - Lentivirus-based. It makes you wonder what competence is floating around in the corridors of certain big pharma. Generation 1 technologies in phase 1 and 2 are now phasing out. It is therefore important that Circio takes its time and makes the right choices now as generation 2 develops. They see that a lot of new things are coming - AAV Capsides, LNP in various variants, peptide technology and others, but the actual engine that creates durability and high efficacy, that is mainly circVec which stands out. Those who have bought Orna and Orbital et al are probably trying as long as possible to cling to synthetic due to large investments, but there is only one DNA based - circVec - that outperforms everything currently according to what is known. A better starting point for creating FOMO among big pharma is hard to have. You cannot trade towards a sudden piece of news. You can only hedge against it by holding. Through thick and thin. Circio has top international competence, possibly better than what is in certain big pharma. Have a good weekend.What is happening in Circio is not happening on the stock exchange - it is happening in the lab in Sweden and in the minds of Wiklund, Hansen, Levitsky, O'Leary - that is only something they have control over. DnB has invested via funds and now they have also invited Circio to an investor presentation. This has been outside their control and Pareto took the case and raised the money. DnB is probably trying to position themselves now - well ok. But you have a point - use Nordnet - I used DnB before and then I felt that the trades were controlled via internal portfolio. The trades were not registered on the stock exchange when they were made. I didn't understand it. So I got suspicious - have no proof - that they were made against own customers/portfolio and not on the open stock exchange. DnB never again for a small investor.
·5 t sittenLooking at today's chart for CRNA, it is impossible not to notice the sharp, rapid fluctuations. Such sudden jumps and drops are largely due to algorithms and trading bots running loops based on short-term indicators like STO and MACD. When the price is tested towards the 10 level, they trigger automatic triggers.
·6 t sittenVerily I say unto you, it is tough to be long-term at times......
Long-term? Most people on this forum have entered the stock in the last 3-9 months...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
59 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten · MuokattuTraders week. A lot is happening now in Circio. Many collaborations, many results and strategies to be evaluated. Remember that there have been a flurry of failed studies in gene and cell therapy studies. Initiated too early a couple three years ago. Novartis, Lilly etc are cutting studies in phase 2, Lilly most recently yesterday in Alzheimer's. The arguably worst is last year's Astra Zeneca acquisition of EsoBiotec for 1 billion USD which failed with fatalities less than 6 months after payment in phase 1 - Lentivirus-based. It makes you wonder what competence is floating around in the corridors of certain big pharma. Generation 1 technologies in phase 1 and 2 are now phasing out. It is therefore important that Circio takes its time and makes the right choices now as generation 2 develops. They see that a lot of new things are coming - AAV Capsides, LNP in various variants, peptide technology and others, but the actual engine that creates durability and high efficacy, that is mainly circVec which stands out. Those who have bought Orna and Orbital et al are probably trying as long as possible to cling to synthetic due to large investments, but there is only one DNA based - circVec - that outperforms everything currently according to what is known. A better starting point for creating FOMO among big pharma is hard to have. You cannot trade towards a sudden piece of news. You can only hedge against it by holding. Through thick and thin. Circio has top international competence, possibly better than what is in certain big pharma. Have a good weekend.What is happening in Circio is not happening on the stock exchange - it is happening in the lab in Sweden and in the minds of Wiklund, Hansen, Levitsky, O'Leary - that is only something they have control over. DnB has invested via funds and now they have also invited Circio to an investor presentation. This has been outside their control and Pareto took the case and raised the money. DnB is probably trying to position themselves now - well ok. But you have a point - use Nordnet - I used DnB before and then I felt that the trades were controlled via internal portfolio. The trades were not registered on the stock exchange when they were made. I didn't understand it. So I got suspicious - have no proof - that they were made against own customers/portfolio and not on the open stock exchange. DnB never again for a small investor.
- ·5 t sittenLooking at today's chart for CRNA, it is impossible not to notice the sharp, rapid fluctuations. Such sudden jumps and drops are largely due to algorithms and trading bots running loops based on short-term indicators like STO and MACD. When the price is tested towards the 10 level, they trigger automatic triggers.
- ·6 t sittenVerily I say unto you, it is tough to be long-term at times......Long-term? Most people on this forum have entered the stock in the last 3-9 months...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 312 | ||
| 153 | ||
| 783 | ||
| 167 | ||
| 2 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
59 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten · MuokattuTraders week. A lot is happening now in Circio. Many collaborations, many results and strategies to be evaluated. Remember that there have been a flurry of failed studies in gene and cell therapy studies. Initiated too early a couple three years ago. Novartis, Lilly etc are cutting studies in phase 2, Lilly most recently yesterday in Alzheimer's. The arguably worst is last year's Astra Zeneca acquisition of EsoBiotec for 1 billion USD which failed with fatalities less than 6 months after payment in phase 1 - Lentivirus-based. It makes you wonder what competence is floating around in the corridors of certain big pharma. Generation 1 technologies in phase 1 and 2 are now phasing out. It is therefore important that Circio takes its time and makes the right choices now as generation 2 develops. They see that a lot of new things are coming - AAV Capsides, LNP in various variants, peptide technology and others, but the actual engine that creates durability and high efficacy, that is mainly circVec which stands out. Those who have bought Orna and Orbital et al are probably trying as long as possible to cling to synthetic due to large investments, but there is only one DNA based - circVec - that outperforms everything currently according to what is known. A better starting point for creating FOMO among big pharma is hard to have. You cannot trade towards a sudden piece of news. You can only hedge against it by holding. Through thick and thin. Circio has top international competence, possibly better than what is in certain big pharma. Have a good weekend.What is happening in Circio is not happening on the stock exchange - it is happening in the lab in Sweden and in the minds of Wiklund, Hansen, Levitsky, O'Leary - that is only something they have control over. DnB has invested via funds and now they have also invited Circio to an investor presentation. This has been outside their control and Pareto took the case and raised the money. DnB is probably trying to position themselves now - well ok. But you have a point - use Nordnet - I used DnB before and then I felt that the trades were controlled via internal portfolio. The trades were not registered on the stock exchange when they were made. I didn't understand it. So I got suspicious - have no proof - that they were made against own customers/portfolio and not on the open stock exchange. DnB never again for a small investor.
- ·5 t sittenLooking at today's chart for CRNA, it is impossible not to notice the sharp, rapid fluctuations. Such sudden jumps and drops are largely due to algorithms and trading bots running loops based on short-term indicators like STO and MACD. When the price is tested towards the 10 level, they trigger automatic triggers.
- ·6 t sittenVerily I say unto you, it is tough to be long-term at times......Long-term? Most people on this forum have entered the stock in the last 3-9 months...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 312 | ||
| 153 | ||
| 783 | ||
| 167 | ||
| 2 200 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt